Japanese Riken And Toppan Conduct Trials Using DNA To Select AIDS Drugs
This article was originally published in PharmAsia News
Executive SummaryJapanese Rikakaku Institute and printing company Toppan June 22 initiated a clinical trial in Thailand to forecast efficacy and adverse effects of AIDS drugs based on patient DNA types. The trial will use gene analysis device developed by Toppan subsidiary Rikan Genesis. The two companies aim to confirm the effectiveness of the device through the trials and market the product in Thailand where many AIDS patents are suffering adverse effects of AIDS drugs. (Click here for more - Japanese language
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.